Rigel Pharmaceuticals, Inc.
http://www.rigel.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Rigel Pharmaceuticals, Inc.
HUTCHMED Switches Clinical Strategy To Rely On Partnerships For Late-Stage Assets In US
Having initiated China-only Phase III trials with three oncology and autoimmune drug candidates, HUTCHMED is looking for partnerships to take the molecules to the clinic in the US.
EU Court Rejects Appeals Over Perindopril Settlements
In long-running litigation over perindopril ‘pay for delay’ settlements, appeals have been refused and certain earlier findings by Europe’s general court have been set aside in a fresh ruling by the Court of Justice of the EU.
India Pharma Chiefs On Supply Chain Learnings From Auto Sector, New ‘PAGE’ On Skilling
Leaders from India’s top drug makers discuss efforts to operationalize a world-class skilling institute, backed by tie-ups with organizations like the PDA, ISPE and also taking a leaf out of the automobile industry’s book to build supply chain resilience. They also exuded confidence on moving up the innovation value chain.
Who’s Hired? Lupin Appoints CEO To New API CDMO Subsidiary
Lupin has selected a CEO to lead its fresh API CDMO business venture, while the UK’s off-patent group BGMA has appointed a new vice-chair. Meanwhile, ChemWerth has welcomed a familiar face as its new president and Coherus has elected a new board member with a focus on immuno-oncology.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice